SCHEMBL24619503

SCHEMBL24619503

CNC(=O)c1ccc(-c2cn3c(n2)sc2cc(C(=O)NC(C)CCO)ccc23)cc1

nearest known ligand 0.66

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 7/20 0.56
▸ THRB P10828 4/20 0.54
▸ RXFP1 Q9HBX9 2/20 0.54
▸ MAPT P10636 2/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ TP53 P04637 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24619717 0.90 LMNA (0.57) LMNATHRBRXFP1MAPTSMN1; SMN2
SCHEMBL24619716 0.90 LMNA (0.57) LMNATHRBRXFP1MAPTSMN1; SMN2
SCHEMBL24619462 0.88 LMNA (0.58) LMNATHRBRXFP1MAPTSMN1; SMN2
SCHEMBL24741290 0.87 LMNA (0.67) LMNATHRBRXFP1MAPTTP53
Formic Acid SCHEMBL29925099 0.86 LMNA (0.54) LMNATHRBRXFP1MAPTSMN1; SMN2
SCHEMBL24619752 0.85 LMNA (0.57) LMNATHRBRXFP1MAPTSMN1; SMN2
SCHEMBL24619755 0.85 LMNA (0.57) LMNATHRBRXFP1MAPTSMN1; SMN2
SCHEMBL24619246 0.85 LMNA (0.58) LMNATHRBRXFP1MAPTSMN1; SMN2
SCHEMBL24619768 0.84 LMNA (0.65) LMNATHRBMAPTSMN1; SMN2TP53
SCHEMBL24619764 0.84 LMNA (0.65) LMNATHRBMAPTSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404283-B2 c-MYC mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-09-02 — — US disclosed
US-20250129100-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-24 — — US disclosed
WO-2024010762-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2024-01-11 — — WO disclosed
EP-4274569-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2023-11-15 — — EP disclosed
CN-116635028-A Modulators of c-MYC mRNA translation and their use in the treatment of cancer 艾尼莫生物科技公司 2023-08-22 — — CN disclosed
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-11-24 — — US disclosed
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-11-24 — — US disclosed
WO-2022150316-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-07-14 — — WO disclosed
WO-2022150316-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-07-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 LMNA 1484/4885THRB 2134/4885RXFP1 4840/4885
US-20250129100-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 LMNA 1484/4885THRB 2134/4885RXFP1 4840/4885
US-12404283-B2 c-MYC mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 LMNA 1484/4885THRB 2134/4885RXFP1 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback